Side-by-side comparison of AI visibility scores, market position, and capabilities
SF YC W20/S21 men's GLP-1 obesity telemedicine at $50M+ ARR cashflow positive 24 months with $130K total raised; competing with Ro and Hims for men's obesity treatment at massive capital efficiency targeting 1M patients by end 2026.
Fella Health is a San Francisco-based men's obesity telemedicine platform — bootstrapped with minimal external funding ($130,000 seed from Y Combinator, Global Founders Capital, AngelList, and founders of Indeed, Curative, and Alan) — providing men with obesity and metabolic health challenges with a subscription-based direct-to-patient treatment program combining FDA-approved GLP-1 medications (semaglutide and tirzepatide), psychological strengthening, and behavioral interventions for significant weight loss and metabolic health improvement. Having achieved over $50 million in annual recurring revenue and cashflow positive operations for 24 months, with 76+ employees and a mission to serve 1 million men by end of 2026, Fella also operates Delilah Health for women through the same clinical model. Y Combinator W20/S21 backed.
Mass spectrometry sample prep and data science platform delivering 100x productivity for biopharma protein analysis; $9.1M from Merck Digital Sciences Studio, NIH, and YC at $1.8M revenue.
Andson Biotech is an Atlanta-based healthcare technology company providing mass spectrometry solutions for biopharma and biomanufacturing — offering the DynaCHIP hardware system (a novel mass spectrometry sample preparation platform) and DynaMARK data science module that together deliver up to 100x productivity improvements in protein and biomolecule analysis workflows compared to conventional mass spectrometry setups. Backed by Y Combinator, Merck Digital Sciences Studio, and NIH with $9.1 million raised, Andson achieved $1.8 million in revenue as of December 2024.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.